Extracellular adenosine (ADO), generated from ATP/ADP through the concerted action of the ecto-enzymes CD39 and CD73, elicits autocrine and paracrine effects mediated by type 1 purinergic receptors. We have tested whether the expression of CD39 and CD73 by chronic lymphocytic leukemia (CLL) cells activates an adenosinergic axis impacting on growth and survival. By immunohistochemistry, CD39 is widely expressed in CLL lymph nodes, whereas CD73 is restricted to proliferation centers. CD73 expression is highest on Ki-67(+) CLL cells, adjacent to T lymphocytes and further localized to perivascular areas. CD39(+)/CD73(+) CLL cells generate ADO from ADP, in a time- and concentration-dependent manner. In peripheral blood, CD73 expression occurs in 97/299 (32%) CLL patients and pairs with CD38 and ZAP-70 expression. CD73-generated extracellular ADO activates type 1 purinergic A2A receptors, which are constitutively expressed by CLL cells and which are further elevated in proliferating neoplastic cells. Activation of the ADO receptors increases cytoplasmic cAMP levels, inhibiting chemotaxis and limiting spontaneous and/or drug-induced apoptosis of CLL cells. These data are consistent with the existence of an autocrine adenosinergic loop, which supports engraftment of leukemic cells in growth-favorable niches, while simultaneously protecting from the action of chemotherapeutic agents.

CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death

SERRA, SARA;HORENSTEIN, ALBERTO;VAISITTI, TIZIANA;BRUSA, Davide;COSCIA, Marta;INGHIRAMI, Giorgio;MALAVASI, Fabio;DEAGLIO, Silvia
2011

Abstract

Extracellular adenosine (ADO), generated from ATP/ADP through the concerted action of the ecto-enzymes CD39 and CD73, elicits autocrine and paracrine effects mediated by type 1 purinergic receptors. We have tested whether the expression of CD39 and CD73 by chronic lymphocytic leukemia (CLL) cells activates an adenosinergic axis impacting on growth and survival. By immunohistochemistry, CD39 is widely expressed in CLL lymph nodes, whereas CD73 is restricted to proliferation centers. CD73 expression is highest on Ki-67(+) CLL cells, adjacent to T lymphocytes and further localized to perivascular areas. CD39(+)/CD73(+) CLL cells generate ADO from ADP, in a time- and concentration-dependent manner. In peripheral blood, CD73 expression occurs in 97/299 (32%) CLL patients and pairs with CD38 and ZAP-70 expression. CD73-generated extracellular ADO activates type 1 purinergic A2A receptors, which are constitutively expressed by CLL cells and which are further elevated in proliferating neoplastic cells. Activation of the ADO receptors increases cytoplasmic cAMP levels, inhibiting chemotaxis and limiting spontaneous and/or drug-induced apoptosis of CLL cells. These data are consistent with the existence of an autocrine adenosinergic loop, which supports engraftment of leukemic cells in growth-favorable niches, while simultaneously protecting from the action of chemotherapeutic agents.
BLOOD
118
23
6141
6152
http://bloodjournal.hematologylibrary.org/content/early/2011/10/13/blood-2011-08-374728.long
5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Antigens, CD; Antineoplastic Agents, Phytogenic; Apyrase; Autocrine Communication; Cell Death; Cell Differentiation; Cell Movement; Cell Survival; Etoposide; Extracellular Space; GPI-Linked Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Paracrine Communication; Receptor, Adenosine A2A; Tumor Cells, Cultured; Biochemistry; Immunology; Hematology; Cell Biology
Serra S; Horenstein AL; Vaisitti T; Brusa D; Rossi D; Laurenti L; D'Arena G; Coscia M; Tripodo C; Inghirami G; Robson SC; Gaidano G; Malavasi F; Deaglio S.
File in questo prodotto:
File Dimensione Formato  
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death_2011.pdf

non disponibili

Tipo di file: PDF EDITORIALE
Dimensione 1.9 MB
Formato Adobe PDF
1.9 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/92523
Citazioni
  • ???jsp.display-item.citation.pmc??? 60
  • Scopus 109
  • ???jsp.display-item.citation.isi??? 105
social impact